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Plasma fibrinogen: now also an antidepressant response
marker?
D Martins-de-Souza1,2,3, G Maccarrone1, M Ising1, S Kloiber1, S Lucae1, F Holsboer1 and CW Turck1
Major depressive disorder (MDD) is one of the leading causes of global disability. It is a risk factor for noncompliance with medical
treatment, with about 40% of patients not responding to currently used antidepressant drugs. The identification and clinical
implementation of biomarkers that can indicate the likelihood of treatment response are needed in order to predict which patients
will benefit from an antidepressant drug. While analyzing the blood plasma proteome collected from MDD patients before the
initiation of antidepressant medication, we observed different fibrinogen alpha (FGA) levels between drug responders and
nonresponders. These results were replicated in a second set of patients. Our findings lend further support to a recently identified
association between MDD and fibrinogen levels from a large-scale study.
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INTRODUCTION
Major depressive disorder (MDD) is a leading cause of global
disability and a risk factor for noncompliance with medical
treatment.1 As a multivariate disorder presenting a wide range of
symptoms, MDD treatment success varies among patients. About
40% of MDD patients do not respond to current treatments.
Moreover, there is a high rate of relapse and treatment resistance,2
and MDD patients have a high risk of attempting suicide.3
The identification and clinical implementation of biomarkers
that can indicate the likelihood of treatment response are needed
to improve this situation.4 In a recent article, Wium-Andersen
et al.5 reported an association of elevated plasma fibrinogen levels
and MDD. In the present study, we have asked the question
whether fibrinogen levels can also serve as a predictive marker for
the antidepressant treatment response. We used a mass
spectrometry-based proteomics screen of blood plasma samples
from MDD patients before antidepressant treatment. We found
altered levels of fibrinogen alpha chain (FGA) in the plasma from
drug responders compared to nonresponders. These differences
were quantified and compared by western blot.
MATERIALS AND METHODS
Subjects
Initially, we analyzed the proteome of plasma specimens from 25
inpatients suffering from MDD, who participated in the Munich
Antidepressant Response Signature (MARS) project.6 A first round of
validation was performed in 17 patients—8 responders and 9 nonrespon-
ders, followed by a second round of validation in a separate set of 24
patients—16 responders and 8 nonresponders (Table 1). The two cohorts
were built based on the time of sample collection in the clinic. While the
first round of experiments was performed, samples from the second cohort
were collected with no bias. Details of the study were explained to patients
and a written informed consent was obtained. The study was approved by
the ethics committee of the Medical Faculty at the Ludwig-Maximilians
University Munich. Patients were diagnosed by trained psychiatrists
according to the DSM-IV criteria. Antidepressant treatment outcome was
weekly evaluated with the 21 item version of the Hamilton Rating Scale for
Depression (HAM-D). Response was defined as a 50% or larger reduction of
the HAM-D score after 6 weeks of treatment compared with the HAM-D
score on admission to the hospital of the Max Planck Institute of Psychiatry.
Two patients were discharged with no HAM-D ratings at T6. Their weekly
ratings at an earlier time point were used to classify them as responder or
nonresponder. The mean age for responders and nonresponders was 45
and 47 years, respectively. No significant differences were observed in this
regard between the two groups (P=0.6398, Mann–Whitney). Significant
differences between the two groups were also not observed regarding
body mass index (BMI: P=0.2239, Mann–Whitney), cholesterol levels
(P=0.6883, Mann–Whitney) and gender (P= 1.000, two-sided Fisher’s exact
test). None of the study subjects had diabetes. When admitted to the clinic,
the majority of patients were not taking any anti-inflammatory or
immunosuppresant medications. Only three patients were using nonster-
oidal anti-inflammatory drugs (Supplementary Table 1).
Blood plasma samples
Blood samples were collected shortly after admission to the hospital in
sample tubes containing potassium EDTA. Plasma was separated from
blood using an Accuspin System HystopaqueTM-1077 (Sigma Aldrich,
Taufkirchen, Germany) according to the manufacturer’s protocol and
protein concentrations determined by Bradford assay.
Western blot
Twenty micrograms of total protein extracts from each blood plasma
sample was run individually on a 12% SDS minigel (BioRad, Hercules, CA,
USA). Proteins were transferred to Immobilon PVDF membrane (Millipore,
Bedford, MA, USA) at 100 V for 1 h using a cooling system. Membranes
were treated with 5% Carnation Instant Nonfat Dry Milk in TBS-T for 4 h,
rinsed in TBS-T three times for 20min and incubated with an FGA antibody
(Abcam, Cambridge, UK) at a 1:1000 dilution in TBS-T overnight at 4 °C.
After the incubation, membranes were washed twice for 15min with TBS-T.
Next, membranes were incubated with an anti-c-MYC-peroxidase antibody
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(GE Healthcare, Uppsala, Sweden) for 40min at RT, washed with water and
TBS-T, and incubated with ECL solution (GE Healthcare) for 1 min.
Membranes were subsequently scanned using a Gel Doc XR+ System
(BioRad). The optical densities of the FGA band were assessed using
Quantity One software (BioRad). Afterwards, the Immobilon PVDF
membrane was stained with Coomassie Blue to ascertain equal protein
loading in each gel lane. In addition, the Coomassie Blue-stained serum
albumin protein band was used as an internal control for equal protein
loading.
Statistics
All analyses were carried out using SPSS statistical software (IBM, Armonk,
NY, USA). According to the D’Agostino & Pearson normality test, the two
groups evaluated here presented a normal distribution. For the first group,
the P-value for nonresponders is 0.6100 and for responders 0.3716; for the
second group, the P-value for nonresponders is 0.7213 and for responders
0.5509. Considering that 95% of the Gaussian distributed samples should
be within two s.d. of the mean, values that differed more than two s.d.
from the mean were excluded from the analysis (Chauvenet’s Criterion).
Differences between the groups were assessed using analysis of
covariance (ANCOVA) considering BMI and age as covariates. Po0.05
was considered significant.
RESULTS AND DISCUSSION
The plasma proteome analyses by mass spectrometry of
antidepressant responders and nonresponders revealed altered
FGA levels at baseline (data not shown). In the present study, we
confirmed this result by western blot analysis of crude plasma
samples from two separate patient groups (Table 1 and Figure 1).
Table 1. Patients’ clinical data including gender, age, BMI, plasma cholesterol levels and HAM-D
Patient ID Gender Age BMI Cholesterol HAM-D T0 HAM-D T6 Western blot relative signal
First experiment
Nonresponders
1 M 48 25.15 207 29 22 67.37
2 M 51 25.39 187 27 22 49.30
3 M 28 28.28 187 26 14 58.03
4 M 58 27.58 215 36 35 60.41
5 F 33 20 203 24 18 64.59
6 F 53 24.49 211 28 22 59.27
7 F 54 19.61 192 27 17 68.12
8 F 39 26.76 219 35 28 60.20
Responders
9 F 70 24.73 208 35 11 52.99
10 M 31 25 214 21 0 46.30
11 M 68 28.08 215 32 3 52.82
12 F 36 19.72 194 20 6 57.45
13 F 25 18.71 154 28 1 55.81
14 M 67 23.12 171 38 3 50.86
15 F 21 18.59 114 33 0 36.01
16 F 41 20 175 30 7 36.88
17 M 33 28.41 123 33 13 31.39
Second experiment
Nonresponders
18 M 75 23.80 172 28 16 65.07
19 F 36 24.80 135 21 14 66.15
20 M 53 28.04 162 30 20 53.03
21 F 22 20.25 188 33 23 63.51
22 M 22 25.54 190 22 25 56.01
23 F 43 24.10 190 18 NA 51.74
24 F 68 24.51 185 24 24 57.75
25 M 72 27.28 190 29 25 56.11
Responders
26 F 49 24.98 211 21 2 32.83
27 F 25 20.20 208 34 10 59.28
28 M 43 24.89 181 29 10 51.37
29 M 34 20.05 132 22 0 55.71
30 M 87 26.07 155 27 4 63.12
31 F 39 22.28 136 21 9 64.87
32 F 24 18.75 209 39 14 44.64
33 M 68 24.88 157 21 10 55.68
34 M 58 28.09 210 34 8 50.45
35 M 31 23.80 207 41 20 49.50
36 M 44 26.94 211 25 0 37.13
37 M 49 24.30 200 25 9 28.55
38 M 62 24.38 207 30 10 32.66
39 F 56 24.54 185 28 NA 51.11
40 F 39 27.18 215 25 6 51.10
41 F 35 19.96 124 30 12 51.14
Abbreviations: BMI, body mass index; HAM-D, Hamilton Rating Scale for Depression; F, female; M, male; NA, not applicable.
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As our aim was to find a generic antidepressant response
biomarker, we did not take into account the type of antidepres-
sant used by each patient. Consistent with the results from our
initial mass spectrometry analysis, we found higher FGA levels in
nonresponders compared with responders in both patient groups
(Figures 1a and b). BMI and age were considered as covariates and
did not influence the results (Figure 1).
Our findings add further support to recently published data on
an association between elevated plasma fibrinogen levels and
depression in 73 367 subjects.5,7 Other studies have also shown an
association of acute phase proteins including fibrinogen with
MDD.8,9 A meta-analysis of plasma cytokine levels in MDD patients
has found elevated TNF-alpha and IL-6 levels in depressed
patients compared with healthy controls.10 Also, C-reactive
protein, IL-1 and IL-6 have been associated with depression.11
All these results suggest an activated inflammatory status in
MDD12 that may affect serotonergic neurotransmission.13,14 Other
studies suggest an association of fibrinogen with MDD pathogen-
esis. Patients with coronary heart disease presenting depression
symptoms tended to have elevated fibrinogen levels.15 Also, male
MDD patients with hypertension had lower fibrinogen levels.16
Our data add one more piece to this puzzle, suggesting that
baseline plasma fibrinogen levels can serve as a biomarker to
gauge the success of antidepressant treatment response.
The expression of fibrinogen in hepatocytes depends on acute
phase inflammatory stimuli.17 Our results show that high plasma
fibrinogen levels are associated with a poor antidepressant
response and indicate that nonresponders present an elevated
inflammatory status compared with responders. Indeed, other
studies also suggest that MDD patients with increased inflamma-
tory protein levels tend to be treatment resistant.18 An increased
production of acute phase proteins, such as fibrinogen, causes the
activation of the indoleamine 2,3 dioxygenase, which catabolizes
tryptophan, thus decreasing serotonin availability.19 High levels of
circulating fibrinogen are also associated with and targeted in the
treatment of cardiovascular disease.20 Similarly, in the case of
antidepressant resistance, MDD patients could be subjected to
medication that modulates fibrinogen levels21,22 before drug
treatment in order to increase the likelihood of response. The
administration of aspirin for example is currently used in the
treatment of cardiovascular diseases. Aspirin promotes fibrinogen
acetylation, which alters its clotting properties.23 Acetylated
fibrinogen is a less active acute phase protein24, which might
affect serotonin levels.
Although preliminary, our data obtained from a naturalistic set
of samples imply that plasma FGA levels are not only of value as a
biomarker for depression5 but can also serve as a predictive
antidepressant response marker. This could have potential for
clinical implementation following validation in larger sample
cohorts.
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